1.22
price up icon0.00%   0.00
pre-market  Pre-market:  1.22  
loading
Macrogenics Inc stock is traded at $1.22, with a volume of 714.00K. It is up +0.00% in the last 24 hours and down -50.41% over the past month.
See More
Previous Close:
$1.22
Open:
$1.2
24h Volume:
714.00K
Relative Volume:
1.08
Market Cap:
$76.97M
Revenue:
$139.77M
Net Income/Loss:
$-97.62M
P/E Ratio:
-0.7722
EPS:
-1.58
Net Cash Flow:
$-61.71M
1W Performance:
-21.79%
1M Performance:
-50.41%
6M Performance:
-65.44%
1Y Performance:
-90.83%
1-Day Range:
Value
$1.18
$1.25
1-Week Range:
Value
$1.17
$1.5407
52-Week Range:
Value
$1.17
$19.54

Macrogenics Inc Stock (MGNX) Company Profile

Name
Name
Macrogenics Inc
Name
Phone
301-251-5172
Name
Address
9704 MEDICAL CENTER DRIVE, Rockville, MD
Name
Employee
0
Name
Twitter
@macrogenics
Name
Next Earnings Date
2025-03-07
Name
Latest SEC Filings
Name
MGNX's Discussions on Twitter

Compare MGNX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
MGNX
Macrogenics Inc
1.22 76.97M 139.77M -97.62M -61.71M -1.58
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
483.49 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
625.60 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
583.62 35.60B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
266.83 34.53B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
274.78 29.15B 3.81B -644.79M -669.77M -6.24

Macrogenics Inc Stock (MGNX) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-07-24 Downgrade JMP Securities Mkt Outperform → Mkt Perform
Aug-01-24 Downgrade BTIG Research Buy → Neutral
Jul-31-24 Downgrade B. Riley Securities Buy → Neutral
Jul-31-24 Downgrade Guggenheim Buy → Neutral
May-10-24 Downgrade BMO Capital Markets Outperform → Market Perform
May-10-24 Downgrade Stifel Buy → Hold
May-10-24 Downgrade TD Cowen Buy → Hold
Apr-26-24 Initiated B. Riley Securities Buy
Apr-09-24 Upgrade TD Cowen Hold → Buy
Mar-04-24 Reiterated BTIG Research Buy
Feb-14-24 Downgrade H.C. Wainwright Buy → Neutral
Dec-20-23 Upgrade Citigroup Neutral → Buy
Nov-07-23 Upgrade Guggenheim Neutral → Buy
Mar-17-23 Downgrade Guggenheim Buy → Neutral
Nov-22-22 Downgrade Cowen Outperform → Market Perform
Nov-14-22 Upgrade BMO Capital Markets Market Perform → Outperform
Jul-18-22 Downgrade SMBC Nikko Outperform → Neutral
Jul-11-22 Downgrade BMO Capital Markets Outperform → Market Perform
May-04-22 Downgrade Guggenheim Buy → Neutral
Feb-28-22 Upgrade Citigroup Neutral → Buy
Feb-11-22 Initiated BMO Capital Markets Outperform
Feb-04-22 Initiated SMBC Nikko Outperform
Nov-17-21 Resumed Guggenheim Buy
Oct-19-21 Initiated JMP Securities Mkt Outperform
Oct-15-21 Resumed BTIG Research Buy
Apr-26-21 Resumed Credit Suisse Outperform
Mar-12-21 Upgrade Barclays Underweight → Overweight
Dec-22-20 Resumed H.C. Wainwright Buy
Aug-03-20 Downgrade Citigroup Buy → Neutral
Jun-01-20 Upgrade Guggenheim Neutral → Buy
May-26-20 Reiterated H.C. Wainwright Buy
Mar-04-20 Initiated Barclays Underweight
Dec-19-19 Initiated Cantor Fitzgerald Overweight
Dec-18-19 Initiated Cantor Fitzgerald Overweight
Nov-21-19 Downgrade Morgan Stanley Equal-Weight → Underweight
Nov-20-19 Resumed Guggenheim Neutral
May-03-19 Upgrade Wedbush Neutral → Outperform
Apr-12-19 Initiated Guggenheim Neutral
Feb-07-19 Upgrade Citigroup Sell → Buy
Feb-07-19 Downgrade Wedbush Outperform → Neutral
Feb-06-19 Upgrade Raymond James Underperform → Mkt Perform
Feb-04-19 Downgrade Citigroup Neutral → Sell
Dec-10-18 Downgrade Raymond James Outperform → Underperform
Sep-10-18 Resumed BTIG Research Buy
May-31-18 Initiated Evercore ISI Outperform
Mar-05-18 Initiated H.C. Wainwright Buy
Mar-31-17 Initiated Raymond James Outperform
View All

Macrogenics Inc Stock (MGNX) Latest News

pulisher
Mar 30, 2025

MacroGenics, Inc. (NASDAQ:MGNX) Shares Purchased by Charles Schwab Investment Management Inc. - Defense World

Mar 30, 2025
pulisher
Mar 28, 2025

Bank of New York Mellon Corp Has $540,000 Stock Holdings in MacroGenics, Inc. (NASDAQ:MGNX) - Defense World

Mar 28, 2025
pulisher
Mar 28, 2025

HC Wainwright Increases Earnings Estimates for MacroGenics - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

MacroGenics, Inc. (MGNX) Shareholders May Have Been Affected by FraudLevi & Korsinsky Investigates - ACCESS Newswire

Mar 27, 2025
pulisher
Mar 26, 2025

MacroGenics (NASDAQ:MGNX) Price Target Lowered to $2.00 at HC Wainwright - Defense World

Mar 26, 2025
pulisher
Mar 25, 2025

MGNX stock touches 52-week low at $1.88 amid market challenges - Investing.com Australia

Mar 25, 2025
pulisher
Mar 25, 2025

MGNX stock touches 52-week low at $1.88 amid market challenges By Investing.com - Investing.com South Africa

Mar 25, 2025
pulisher
Mar 25, 2025

MacroGenics stock target cut to $2 at H.C. Wainwright By Investing.com - Investing.com Canada

Mar 25, 2025
pulisher
Mar 24, 2025

Extensive-Stage Small Cell Lung Cancer (ESCLC) Clinical - openPR.com

Mar 24, 2025
pulisher
Mar 24, 2025

Macrogenics Inc (NASDAQ: MGNX) Analysts Prediction On How Much It Could Rise - Stocks Register

Mar 24, 2025
pulisher
Mar 24, 2025

MacroGenics, Inc. (NASDAQ:MGNX) Receives $7.63 Consensus Price Target from Analysts - Defense World

Mar 24, 2025
pulisher
Mar 23, 2025

MacroGenics, Inc. (NASDAQ:MGNX) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 23, 2025
pulisher
Mar 23, 2025

MacroGenics’ SWOT analysis: pipeline progress, cash runway extend stock outlook - Investing.com Canada

Mar 23, 2025
pulisher
Mar 23, 2025

StockNews.com Downgrades MacroGenics (NASDAQ:MGNX) to Hold - Defense World

Mar 23, 2025
pulisher
Mar 22, 2025

MacroGenics’ SWOT analysis: pipeline progress, cash runway extend stock outlook By Investing.com - Investing.com South Africa

Mar 22, 2025
pulisher
Mar 21, 2025

MacroGenics Inc’s 2024 Earnings Call Highlights - TipRanks

Mar 21, 2025
pulisher
Mar 21, 2025

MacroGenics axes ADC drug following Phase II failure in prostate cancer - Yahoo

Mar 21, 2025
pulisher
Mar 21, 2025

Macrogenics Inc (MGNX) Q4 2024: Everything You Need to Know Ahea - GuruFocus.com

Mar 21, 2025
pulisher
Mar 21, 2025

Stifel maintains Hold on MacroGenics stock, price target at $6 By Investing.com - Investing.com Canada

Mar 21, 2025
pulisher
Mar 21, 2025

Citizens JMP maintains MacroGenics stock with Market Outperform By Investing.com - Investing.com South Africa

Mar 21, 2025
pulisher
Mar 21, 2025

Citizens JMP maintains MacroGenics stock with Market Outperform - Investing.com India

Mar 21, 2025
pulisher
Mar 21, 2025

MacroGenics (MGNX) Reports Q4 Loss, Lags Revenue Estimates - MSN

Mar 21, 2025
pulisher
Mar 21, 2025

MacroGenics Reports 2024 Financial Results and Progress - TipRanks

Mar 21, 2025
pulisher
Mar 21, 2025

Macrogenics Inc (MGNX) Q4 2024 Earnings Call Highlights: Revenue Surge Amid Rising Expenses - Yahoo Finance

Mar 21, 2025
pulisher
Mar 20, 2025

MacroGenics (MGNX) Q4 2024 Earnings Call Transcript - Yahoo

Mar 20, 2025
pulisher
Mar 20, 2025

MacroGenics (MGNX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance

Mar 20, 2025
pulisher
Mar 20, 2025

MACROGENICS Earnings Results: $MGNX Reports Quarterly Earnings - Nasdaq

Mar 20, 2025
pulisher
Mar 20, 2025

Earnings call transcript: MacroGenics beats Q4 2024 EPS expectations - Investing.com India

Mar 20, 2025
pulisher
Mar 20, 2025

Earnings call transcript: MacroGenics beats Q4 2024 EPS expectations By Investing.com - Investing.com UK

Mar 20, 2025
pulisher
Mar 20, 2025

MacroGenics Inc. (MGNX) reports earnings - Quartz

Mar 20, 2025
pulisher
Mar 20, 2025

MacroGenics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

MacroGenics Inc Provides Update On Corporate Progress And 2024 Financial Results - Marketscreener.com

Mar 20, 2025
pulisher
Mar 20, 2025

Macrogenics Inc (MGNX) Reports Q4 Revenue of $150 Million, Surpa - GuruFocus

Mar 20, 2025
pulisher
Mar 20, 2025

MACROGENICS INC SEC 10-K Report - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

MacroGenics Provides Update on Corporate Progress and 2024 Financial Results - GlobeNewswire

Mar 20, 2025
pulisher
Mar 20, 2025

MacroGenics Triples Revenue to $150M as Cancer Drug Pipeline Advances - StockTitan

Mar 20, 2025
pulisher
Mar 18, 2025

MGNX stock touches 52-week low at $2.15 amid sharp annual decline - Investing.com Australia

Mar 18, 2025
pulisher
Mar 17, 2025

Macrogenics Stock Drops 77% After Study Deaths - The Wall Street Journal

Mar 17, 2025
pulisher
Mar 17, 2025

Class Action Filed Against MacroGenics, Inc. (MGNX) Seeking Recovery for Investors – Contact Levi & Korsinsky - ACCESS Newswire

Mar 17, 2025
pulisher
Mar 13, 2025

MacroGenics (MGNX) to Release Quarterly Earnings on Thursday - Defense World

Mar 13, 2025
pulisher
Mar 13, 2025

MacroGenics at Barclays Conference: Strategic Insights on Pipeline and Partnerships By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 12, 2025

MGNX LAWSUIT ALERT: Levi & Korsinsky Notifies MacroGenics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire

Mar 12, 2025
pulisher
Mar 12, 2025

MacroGenics at Barclays Conference: Strategic Insights on Pipeline and Partnerships - Investing.com

Mar 12, 2025
pulisher
Mar 12, 2025

MGNX Deadline: MGNX Investors with Losses in Excess of $100K Hav - GuruFocus.com

Mar 12, 2025
pulisher
Mar 11, 2025

MacroGenics at Leerink’s Conference: Strategic Pipeline Insights By Investing.com - Investing.com Canada

Mar 11, 2025
pulisher
Mar 09, 2025

MacroGenics, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before September 24, 2024 to Discuss Your RightsMGNX - ACCESS Newswire

Mar 09, 2025
pulisher
Mar 06, 2025

Levi & Korsinsky Notifies Shareholders of MacroGenics, Inc. (MGNX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire

Mar 06, 2025
pulisher
Mar 06, 2025

MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call - GlobeNewswire

Mar 06, 2025

Macrogenics Inc Stock (MGNX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$73.44
price up icon 2.00%
$68.32
price up icon 0.56%
$31.28
price up icon 0.35%
$20.46
price up icon 8.83%
$93.32
price up icon 3.36%
biotechnology ONC
$274.78
price up icon 1.38%
Cap:     |  Volume (24h):